Related Experiment Video
Updated: Aug 8, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Depression as measured by the Beck Depression Inventory-II among injecting drug users
Mark E Johnson1, David B Neal, Christiane Brems
1Department of Psychology, University of Alaska Anchorage, 99508, USA. mejohnson@uaa.alaska.edu
Abstract:
This study conducts a confirmatory factor analysis of the Beck Depression Inventory-II (BDI-II) with a sample of 598 individuals who reported recent injecting drug use. Findings indicate that out of four models tested, the best model for this sample is a three-factor solution (somatic, affective, and cognitive) previously reported by Buckley, Parker, and Heggie. The findings that nearly 50% of participants provided BDI-II scores indicating significant depressive symptomatology reveals that these individuals are in need of treatment for their psychiatric symptoms as well as substance use. Somatic symptoms are endorsed more strongly than affective or cognitive symptoms of depression, suggesting a possible, but yet poorly defined, relationship between depressive symptomatology and drug use that centers on shared somatic symptomatology.
Related Concept Videos
Drug Dependence
Depressive Disorders: MDD and Dysthymia
Depression: Overview
Antidepressant Drugs: MAOIs and Other Agents
Drug Accumulation During Multiple Dosing: Repetitive IV Injections